-
公开(公告)号：KR20180056778A
公开(公告)日：2018-05-29
申请号：KR20187012991
申请日：2016-10-06
Applicant: ONCOTHERAPY SCIENCE INC
Inventor： YAMASHITA SACHIKO , HIKICHI TETSURO
CPC classification number: A61K35/12 , A61K35/17 , A61K38/00 , A61K48/00 , C07K7/06 , C12N5/10 , C12N15/09 , G01N33/15 , G01N33/50
Abstract: 본발명은세포독성 T 세포를유도할수 있는 FOXM1 유래에피톱펩티드를제공한다. 본발명은더 나아가, 상기펩티드를코딩하는폴리뉴클레오티드, 상기펩티드를제시하는항원제시세포, 및상기펩티드를타겟하는세포독성 T 세포뿐만아니라, 항원제시세포또는 CTL의유도방법도제공한다. 본발명은또한유효성분으로서그들을포함하는조성물또는약학적조성물을제공한다. 더나아가, 본발명은본 발명의펩티드, 폴리뉴클레오티드, 항원제시세포, 세포독성 T 세포또는약학적조성물을사용하여암의치료및/또는예방방법, 및/또는이의수술후 재발을예방하는방법을제공한다. 암에대해면역반응을유도하는방법도또한제공한다.
-
公开(公告)号：KR20180055892A
公开(公告)日：2018-05-25
申请号：KR20187012067
申请日：2016-10-06
Applicant: ONCOTHERAPY SCIENCE INC
Inventor： YAMASHITA SACHIKO , HIKICHI TETSURO
CPC classification number: A61K35/15 , A61K35/17 , A61K39/00 , A61K48/00 , C07K7/06 , C07K16/28 , C12N1/00 , C12N15/09
Abstract: 본발명은세포독성 T 세포를유도할수 있는 MPHOSPH1-유래에피톱펩티드를제공한다. 본발명은더 나아가, 상기펩티드를코딩하는폴리뉴클레오티드, 상기펩티드를제시하는항원제시세포, 및상기펩티드를타겟하는세포독성 T 세포뿐만아니라, 항원제시세포또는 CTL의유도방법도제공한다. 본발명은또한유효성분으로서그들을포함하는조성물또는약학적조성물을제공한다. 더나아가, 본발명은본 발명의펩티드, 폴리뉴클레오티드, 항원제시세포, 세포독성 T 세포또는약학적조성물을사용하여암의치료및/또는예방방법, 및/또는이의수술후 재발을예방하는방법을제공한다. 암에대해면역반응을유도하는방법도또한제공한다.
-
公开(公告)号：JP2007191485A
公开(公告)日：2007-08-02
申请号：JP2007058127
申请日：2007-03-08
Applicant: Oncotherapy Science Inc , オンコセラピー・サイエンス株式会社
Inventor： TAWARA HIDEAKI , WADA SATOSHI , TSUNODA TAKUYA
IPC: C07K7/06 , A61K38/00 , A61K39/00 , A61P3/10 , A61P9/00 , A61P9/10 , A61P17/06 , A61P19/02 , A61P27/02 , A61P29/00 , A61P35/00 , A61P35/04 , C07K14/705 , C07K14/71 , C12N5/06 , C12N15/12
CPC classification number: A61K39/0011 , A61K2039/5154 , A61K2039/5156 , A61K2039/5158 , C07K7/06 , C07K14/71
Abstract: PROBLEM TO BE SOLVED: To provide a peptide targeting a VEGF (vascular endothelial growth factor) receptor 2 strongly expressing in an endothelial cell of tumor tissue and effective as a cancer vaccine and provide a medicine containing the peptide and useful for the treatment or prevention of tumor. SOLUTION: The invention provides a peptide or decapeptide composed of a specific amino acid sequence derived from a VEGF receptor 2, a peptide having an amino acid sequence derived from the above amino acid sequences by substitution or addition of one to several amino acids and having cytotoxic T cell inducing activity, and a vaccine containing the peptide as an active component. COPYRIGHT: (C)2007,JPO&INPIT
Abstract translation: 待解决的问题：提供靶向VEGF（血管内皮生长因子）受体2的肽，其在肿瘤组织的内皮细胞中强烈表达，并且作为癌症疫苗有效并提供含有该肽并可用于治疗的药物 或预防肿瘤。 解决方案：本发明提供了由衍生自VEGF受体2的特异性氨基酸序列组成的肽或十肽，其具有通过取代或添加一至几个氨基酸而具有来源于上述氨基酸序列的氨基酸序列的肽 并具有细胞毒性T细胞诱导活性，以及含有肽作为活性成分的疫苗。 版权所有（C）2007，JPO＆INPIT
-
公开(公告)号：US11079386B2
公开(公告)日：2021-08-03
申请号：US16336846
申请日：2017-10-04
Applicant: ONCOTHERAPY SCIENCE, INC.
Inventor： Yosuke Harada , Tatsuki Yokoseki , Yusuke Nakamura
IPC: G01N33/574 , C07K16/28
Abstract: The present invention relates to monoclonal antibodies against FZD10. Furthermore, the present invention provides methods for diagnosing FZD10-related diseases using such an antibody, methods for detecting a FZD10 protein, methods for determining drug efficacy after treatment with FZD10 inhibitors, and methods of screening for subjects in whom treatment with FZD10 inhibitors is highly effective, and provides diagnostic reagents containing such an antibody.
-
公开(公告)号：US20200255474A1
公开(公告)日：2020-08-13
申请号：US16631141
申请日：2018-07-18
Applicant: TOKUSHIMA UNIVERSITY , ONCOTHERAPY SCIENCE, INC.
Inventor： Toyomasa KATAGIRI , Tetsuro YOSHIMARU , Takashi MIYAMOTO , Yasuhide OKAMOTO
Abstract: The present invention provides peptides having a structure in which portions of a dominant-negative peptide of BIG3 which inhibits the interaction between BIG3 and PHB2 are replaced by at least two stapling structures. The peptides of the present invention have excellent cell growth inhibiting activity. The cell growth inhibiting activity lasts longer, compared to a single-stapled peptide. Therefore, the peptides of the present invention have a feature suitable for clinical applications in cancer therapy.
-
Patent Agency Ranking
公开(公告)号：US10669310B2
公开(公告)日：2020-06-02
申请号：US16070896
申请日：2017-01-16
Applicant: TOKUSHIMA UNIVERSITY , ONCOTHERAPY SCIENCE, INC.
Inventor： Toyomasa Katagiri , Takashi Miyamoto , Rie Hayashi
Abstract: The present invention provides peptides containing a structure in which a portion of the dominant negative peptide of BIG3 which inhibits the interaction between BIG3 and PHB2 is substituted with stapling structure(s). Peptides of the present invention have excellent cell growth inhibitory actions. Furthermore, their cell growth inhibitory actions continue for a longer time than the actions of peptides without stapling structures. Therefore, these peptides have features suitable for clinical applications in cancer therapy.
-
公开(公告)号：US20200155596A1
公开(公告)日：2020-05-21
申请号：US16773487
申请日：2020-01-27
Applicant: ONCOTHERAPY SCIENCE, INC.
Inventor： Takuya TSUNODA , Ryuji OSAWA , Sachiko YAMASHITA , Tomohisa WATANABE , Tetsuro HIKICHI
IPC: A61K35/14 , C12N15/09 , C12N5/10 , C07K7/08 , C07K7/06 , C07K16/18 , A61K48/00 , A61K39/00 , A61K35/12
Abstract: The present invention provides KOC1-derived epitope peptides having the ability to induce cytotoxic T cells. The present invention further provides polynucleotides encoding the peptides, antigen-presenting cells presenting the peptides, and cytotoxic T cells targeting the peptides, as well as methods of inducing the antigen-presenting cells or CTLs. The present invention also provides compositions and pharmaceutical compositions containing them as an active ingredient. Further, the present invention provides methods of treating and/or preventing cancer, and/or preventing postoperative recurrence thereof, using the peptides, polynucleotides, antigen-presenting cells, cytotoxic T cells or pharmaceutical compositions of the present invention. Methods of inducing an immune response against cancer are also provided.
-
公开(公告)号：US10576097B2
公开(公告)日：2020-03-03
申请号：US15500895
申请日：2015-07-31
Applicant: ONCOTHERAPY SCIENCE, INC.
Inventor： Takuya Tsunoda , Ryuji Osawa , Sachiko Yamashita , Tomohisa Watanabe , Tetsuro Hikichi
IPC: A61K39/00 , A61K31/7088 , A61K38/00 , A61K48/00 , C12N15/09 , C07K7/06 , C07K7/08 , C12Q1/02 , G01N33/15 , G01N33/50
Abstract: The present invention provides URLC10-derived epitope peptides having the ability to induce cytotoxic T cells. The present invention further provides polynucleotides encoding the peptides, antigen-presenting cells presenting the peptides, and cytotoxic T cells targeting the peptides, as well as methods of inducing the antigen-presenting cells or CTLs. The present invention also provides compositions and pharmaceutical compositions containing them as an active ingredient. Further, the present invention provides methods of treating and/or preventing cancer, and/or preventing postoperative recurrence thereof, using the peptides, polynucleotides, antigen-presenting cells, cytotoxic T cells or pharmaceutical compositions of the present invention. Methods of inducing an immune response against cancer are also provided.
-
公开(公告)号：US20190185575A1
公开(公告)日：2019-06-20
申请号：US16328259
申请日：2017-08-25
Applicant: ONCOTHERAPY SCIENCE, INC.
Inventor： Yosuke HARADA , Suyoun CHUNG , Yusuke NAKAMURA
IPC: C07K16/30 , C12N15/85 , G01N33/573 , G01N33/574
CPC classification number: C07K16/30 , C07K16/18 , C12N15/85 , C12N2015/8518 , G01N33/573 , G01N33/57492 , G01N2800/364 , G01N2800/50 , G01N2800/52
Abstract: The present invention relates to monoclonal antibodies against MELK. Furthermore, the present invention provides methods for diagnosing MELK-associated diseases using the antibodies, methods for detecting the MELK protein, methods for determining the drug efficacy following treatment with a MELK inhibitor, methods of screening for subjects to whom a MELK inhibitor has a high therapeutic effect, and diagnostic reagents containing the antibodies.
-
公开(公告)号：US10206989B2
公开(公告)日：2019-02-19
申请号：US15411115
申请日：2017-01-20
Applicant: OncoTherapy Science, Inc.
Inventor： Yasuharu Nishimura , Yusuke Tomita , Ryuji Osawa
IPC: A61K38/00 , A61K39/00 , C07K14/47 , C12N5/0783 , C07K16/28 , C07K7/06 , C07K7/08 , C07K14/00 , C07K16/30 , C12N5/078
Abstract: Isolated CDCA1-derived epitope peptides having Th1 cell inducibility are disclosed herein. Such peptides can be recognized by MHC class II molecules and induce Th1 cells. In preferred embodiments, such a peptide of the present invention can promiscuously bind to MHC class II molecules and induce CDCA1-specific cytotoxic T lymphocytes (CTLs) in addition to Th1 cells. Such peptides are thus suitable for use in enhancing immune response in a subject, and accordingly find use in cancer immunotherapy, in particular, as cancer vaccines. Also disclosed herein are polynucleotides that encode any of the aforementioned peptides, APCs and Th1 cells induced by such peptides and methods of induction associated therewith. Pharmaceutical compositions that comprise any of the aforementioned components as active ingredients find use in the treatment and/or prevention of cancers or tumors.
-
-
-
-
-
-
-
-
-
Search Results
2001
records
(took 0.037 seconds)
